Media

Nanostics is EXCITED to announce Mike Schoenberger as its newest Board Member! We also send a huge THANK YOU to outgoing board member Dale Klein for his dedicated service.

PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. Nanostics is excited to work with this Partner to reach the recruitment numbers and diversity goals of the clinical study.

PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida.

Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting.

Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.

Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting.

The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic’s research into diagnostic testing for prostate cancer.

News Medical Lifesciences – ClarityDX Prostate cancer diagnostic test validation study gets a boost in recruitment thanks to concurrent fundraising campaigns.

The Nanostics & APCaRI co-sponsored ClarityDX Prostate clinical validation study is expanding into the US by opening the Daytona Beach, Florida Century Clinical Research, Inc. recruitment site.

1 of 7 Canadian men is diagnosed with prostate cancer each year. We cannot emphasize enough on how important it is to get tested each year. Nanostics has come up with a non-invasive diagnostic test to bring clarity to healthcare decisions. Their core technology is in development to be able to diagnose prostate cancer from a simple blood test.

Nanostics’ core technology, ClarityDX, combines a sensitive extracellular vesicle detection platform with advanced machine learning to diagnose a disease from a simple blood test.

Ana Pena wrote for the Prostate Cancer News Today: The company says the diagnostic tool has the potential to spare many men unnecessary biopsies and treatments.

NEWS STAFF REPORT: Blood test predicts aggressive prostate cancer with greater accuracy and less patient discomfort.

CSO Desmond Pink discusses Nanostics’ productive partnership with DynaLIFE Medical labs’ Translational Research Program- a key relationship to bring ClarityDX to market.

A local startup with plans to market a more accurate prostate cancer screening test is one of the first businesses to set up shop in a new downtown shared lab space for health tech companies.

Alberta scientists, at Nanostics, have created a blood test that could make a significant impact in the way patients are tested and treated for prostate cancer.

1.3M North American men get biopsies each year checking for prostate cancer, many of them unnecessary. UofA researchers want to change that with a new test that relies on GPU computing.

A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.

A new diagnostic will allow men to bypass painful biopsies to test for aggressive prostate cancer.

Alberta men diagnosed with prostate cancer could soon have a better blood test to help determine if they can bypass a painful and invasive biopsy.

The PSA test for prostate cancer has been linked to unnecessary treatments and biopsies. That’s prompted researchers to start developing a more accurate prostate cancer detection tool.